Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Erin M. Paradis"'
Autor:
Erin M. Paradis, Oleg Tikhonov, Xin Cao, Susanna M. Kharit, Aleksandr Fokin, Heather L. Platt, Frederick Wittke, Veronika Jotterand
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 11, Pp 4183-4189 (2021)
Varicella (chickenpox) is a common, highly contagious disease caused by primary infection with varicella zoster virus (VZV), which can result in bacterial superinfection, central nervous system complications, and hospitalization. Stage 2 of this Phas
Externí odkaz:
https://doaj.org/article/57db6a357e144bcaa72e0be7e40222e1
Autor:
Erin M. Paradis, Oleg Tikhonov, Xin Cao, Susanna M. Kharit, Aleksandr Fokin, Heather L. Platt, Natalie Banniettis
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 11, Pp 4177-4182 (2021)
Varicella (chickenpox) is a common, highly contagious disease caused by primary infection with varicella zoster virus (VZV). Adults typically experience more severe symptoms than children and have a higher risk of developing complications. Stage 1 of
Externí odkaz:
https://doaj.org/article/f9243491d87149dab0b987fdc6d7b628
Autor:
Aleksandr Fokin, Oleg Tikhonov, Erin M. Paradis, Frederick Wittke, Veronika Jotterand, Susanna M. Kharit, Heather L. Platt, Xin Cao
Publikováno v:
Human vaccinesimmunotherapeutics. 17(11)
Varicella (chickenpox) is a common, highly contagious disease caused by primary infection with varicella zoster virus (VZV), which can result in bacterial superinfection, central nervous system complications, and hospitalization. Stage 2 of this Phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::894ea8a69374574968e04668b2626e76
https://pubmed.ncbi.nlm.nih.gov/34702124
https://pubmed.ncbi.nlm.nih.gov/34702124
Autor:
Jill Hutzelmann, Christopher Lines, Mary Chengan-Liu, W. Joseph Herring, Thomas Roth, Duane B. Snavely, David Michelson, James K. Walsh, Erin M. Paradis, Martin A. Cohn, Ruth M. Benca, Andrew D. Krystal, Ellen Snyder
Publikováno v:
The Lancet Neurology. 13:461-471
Summary Background Suvorexant (MK-4305) is an orexin receptor antagonist shown to be efficacious for insomnia over 3 months. We aimed to assess its clinical profile during and after 1 year of treatment. Methods We did a randomised, placebo-controlled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c7a74b06348a9b4534e64a361b6a28f
https://doi.org/10.1016/s1474-4422(14)70053-5
https://doi.org/10.1016/s1474-4422(14)70053-5